12,222 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Acquired by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,222 shares of the company's stock, valued at approximately $979,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Essex Investment Management Co. LLC raised its position in shares of PROCEPT BioRobotics by 0.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company's stock valued at $6,489,000 after buying an additional 228 shares in the last quarter. Values First Advisors Inc. bought a new stake in PROCEPT BioRobotics during the third quarter worth $27,000. Arizona State Retirement System boosted its holdings in shares of PROCEPT BioRobotics by 2.8% in the 2nd quarter. Arizona State Retirement System now owns 12,840 shares of the company's stock valued at $784,000 after purchasing an additional 350 shares in the last quarter. KBC Group NV increased its stake in shares of PROCEPT BioRobotics by 32.6% in the 3rd quarter. KBC Group NV now owns 1,531 shares of the company's stock valued at $123,000 after purchasing an additional 376 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PROCEPT BioRobotics by 4.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company's stock valued at $606,000 after purchasing an additional 408 shares during the last quarter. Institutional investors own 89.46% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a "hold" rating and a $95.00 price objective for the company. TD Cowen upped their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. Wells Fargo & Company upped their price objective on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. Piper Sandler restated an "overweight" rating and set a $75.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Finally, Truist Financial restated a "buy" rating and set a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of "Moderate Buy" and an average price target of $89.50.

PROCEPT BioRobotics Trading Down 2.0 %

PROCEPT BioRobotics stock traded down $1.98 during trading hours on Thursday, hitting $97.29. The stock had a trading volume of 519,422 shares, compared to its average volume of 656,404. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of -49.89 and a beta of 1.01. PROCEPT BioRobotics Co. has a one year low of $33.45 and a one year high of $103.81. The business's 50 day simple moving average is $83.40 and its 200-day simple moving average is $73.29.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.09. The firm had revenue of $58.40 million during the quarter, compared to the consensus estimate of $53.30 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business's quarterly revenue was up 66.4% on a year-over-year basis. During the same period last year, the company earned ($0.51) earnings per share. On average, equities analysts predict that PROCEPT BioRobotics Co. will post -1.74 EPS for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, Director Antal Rohit Desai sold 33,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $96.60, for a total value of $3,187,800.00. Following the completion of the sale, the director now owns 231,363 shares of the company's stock, valued at approximately $22,349,665.80. This represents a 12.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Kevin Waters sold 25,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $72.47, for a total value of $1,811,750.00. Following the completion of the sale, the chief financial officer now directly owns 96,096 shares of the company's stock, valued at approximately $6,964,077.12. The trade was a 20.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 561,773 shares of company stock worth $49,073,125. 17.40% of the stock is currently owned by insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).